Interactive Features

Test Your Knowledge

Quiz: Nomograms Developed to Predict Recurrences in Patients with T1 Melanomas

03/26/2021

True or False: The nomograms in this study can identify T1 melanoma patients at higher risk of either local, regional or distant recurrence.

True or False: The nomograms in...

03/26/2021

Oncology

Test Your Knowledge

Quiz: Does Cosibelimab Yield Benefit mCSCC?

09/22/2020

True or False: Cosibelimab has a predictable and manageable safety profile and demonstrated robust clinical activity in mCSCC patient, including durable complete and partial responses.

True or False: Cosibelimab has a...

09/22/2020

Oncology

Test Your Knowledge

Quiz: Promising Advances in the Melanoma Space May Lead to Improved Patient Outcomes

09/02/2020

Treatments for melanoma brain metastasis changed between 2007 and 2016 with the advent of new radiotherapy techniques, targeted therapeutic agents, and ______ ?

Treatments for melanoma brain...

09/02/2020

Oncology

Test Your Knowledge

Quiz: Pembrolizumab for the Treatment of cSCC

07/20/2020

True or False: Has pembrolizumab been approved by the FDA for use in patients with cSCC?

True or False: Has pembrolizumab...

07/20/2020

Oncology

Test Your Knowledge

Quiz: Combining Low-Dose Ipilimumab With Pembrolizumab in Melanoma

06/22/2020

True or False: In a phase 2 study, combining low-dose ipilimumab with pembrolizumab led to significant antitumor activity in patients with melanoma that progressed with a PD1 antibody.

True or False: In a phase 2...

06/22/2020

Oncology

Test Your Knowledge

Quiz: What Factors Increase Risk for AEs in Patients With Melanoma?

05/25/2020

True or False: The risk for immune-related adverse events in patients with advanced melanoma varies based on immune checkpoint inhibitor type and dose.

True or False: The risk for...

05/25/2020

Oncology

Test Your Knowledge

Quiz: Can Adverse Events Indicate Pembrolizumab Activity in Stage III Melanoma?

03/06/2020

True or False: Immune-related adverse events can be indicative of pembrolizumab activity in patients with high-risk, stage III melanoma.

True or False: Immune-related...

03/06/2020

Oncology

Test Your Knowledge

Quiz: Mohs Micrographic Surgery vs Traditional Excision for Melanoma

02/13/2020

True or False: Compared with excision, Mohs micrographic surgery moderately improves overall survival in patients with early-stage invasive melanoma.

True or False: Compared with...

02/13/2020

Oncology

Test Your Knowledge

Quiz: Association of Progression of Metastatic Disease and Time to First Distant Recurrence in Melanoma

05/28/2019

True or false: A recent study found no association between progression of metastatic disease and time to first distant recurrence in patients with melanoma.

True or false: A recent study...

05/28/2019

Oncology

Test Your Knowledge

Quiz: Promising First-Line Therapy for Merkel Cell Carcinoma

03/27/2019

Which of the following yielded durable responses, a manageable safety profile, and survival favorable to that of first-line chemotherapy in a recent study of patients with advanced Merkel cell carcinoma?

Which of the following yielded...

03/27/2019

Oncology

Recent News

News

Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise

01/29/2026

Stephanie Holland

Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...

Results from a real-world...

01/29/2026

Oncology

News

Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer

01/29/2026

Emily Estrada

The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.

The addition of elenagen to...

01/29/2026

Oncology

News

Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma

01/28/2026

Stephanie Holland

Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.

Results from the phase 1/2...

01/28/2026

Oncology

News

Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer

01/27/2026

Gina Tomaine

Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.

Antibody-based therapies are...

01/27/2026

Oncology

News

Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial

01/27/2026

Emily Estrada

Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.

Tucatinib plus trastuzumab...

01/27/2026

Oncology

News

TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC

01/27/2026

Emily Estrada

A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.

A TOMOX-bevacizumab combination...

01/27/2026

Oncology

News

ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC

01/27/2026

Gina Tomaine

A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.

A translational study identified...

01/27/2026

Oncology

News

CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT

01/26/2026

Gina Tomaine

Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.

Systemic CSF-1R inhibition...

01/26/2026

Oncology

News

Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer

01/22/2026

Stephanie Holland

Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...

Results from the phase 3...

01/22/2026

Oncology

News

Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer

01/21/2026

Stephanie Holland

Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...

Results from a multicenter,...

01/21/2026

Oncology